The City University of New York (CUNY), New York, NY, and Soterix Medical, Inc., New York, NY, have released an image-guided neuromodulation device. The EEG-Guided High-Definition tES (HD-tES) targets brain regions associated with neuropsychiatric disorders such as depression and chronic pain.

HD-tES, a technology developed by Dr. Marom Bikson and Dr. Lucas Parra at CUNY, delivers targeted, low-intensity electrotherapy non-invasively. By embedding electrodes within a removable cap, the proprietary EEG-Guided HD-tES combines research-grade brain monitoring with clinical-grade brain stimulation.

According to the CUNY researchers, a low-intensity targeted electrical current is known to promote the brain's plasticity, or ability to change with learning. Brain plasticity is considered by some as a basis for facilitating lasting clinical benefit.

The system detects brain activity, diagnoses the brain target, and delivers mild electrotherapy (HD-tES) to the region. Research-grade EEG ensures reliable identification of brain targets while clinical-grade HD-tES supports reliable brain modulation. The number of EEG and HD-tES channels can be scaled up to 64.

"This will improve patient care in a tangible way for a variety of patient populations by providing personalized electroceutical therapy," said Doug Adams, Director of Commercialization at CUNY.